Miles Congreve is the Vice President of Chemistry at Heptares Therapeutics, leading the medicinal chemistry team. Miles obtained a BSc in biological chemistry from Leicester University and a PhD in synthetic chemistry from Cambridge University, before joining Glaxo in 1993. He worked on a range of GPCR, other receptor and enzyme projects in both Lead Optimisation and Hit-to-Lead phases. He then moved to Cambridge in 1999 to manage the GlaxoWellcome Chemistry Laboratory in the University Chemistry Department to work on solid phase library technologies. In this role he initiated a number of collaborations with academics across the UK. In 2001 he joined Astex (now part of Otsuka) to establish the chemistry team and to develop and validate fragment-based drug discovery as a new approach to structure-based drug design and lead identification. He was promoted to Director of Chemistry in 2006. The Astex platform delivered success against a broad range of projects (collaborative and in-house) including at least six clinical candidates. Miles joined Heptares in 2008. The Heptares team has so far identified five pre-clinical or clinical candidates for GPCR targets using fragment and SBDD. In 2015 Miles was co-recipient of the RSC Malcolm Campbell Memorial Award for his part in the seminal contributions to GPCR drug discovery made by Heptares Therapeutics Ltd since the company was founded in 2007. Miles is co-author of over 60 publications and co-inventor on more than 50 patent filings.